BioSpace News Archive

Drug Development

Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting

Puma Biotechnology, Inc., a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma’s drug neratinib at the American Society of Clinical Oncology 2019 Annual Meeting in Chicago.

June 2, 2019
·
10 min read
Drug Development

BerGenBio Presents New Preliminary Clinical and Biomarker Data Showing Durable Response & Median Survival Rates in Phase II Trial With Bemcentinib and KEYTRUDA in Pts With Advanced NSCLC at ASCO 2019

Phase II trial evaluating bemcentinib in combination with KEYTRUDA in advanced NSCLC patients shows 12-month survival data surpassing historical benchmarks in second-line treatment with PD-1 inhibitor monotherapy

June 2, 2019
·
5 min read
Drug Development

IMFINZI® (Durvalumab) is the Only Immunotherapy to Demonstrate Overall Survival at Three Years in Unresectable, Stage III Non-Small Cell Lung Cancer

Data presented at ASCO 2019 showed 57% of patients alive at three years vs. 43.5% on placebo

June 2, 2019
·
17 min read
Drug Development

Phase 3 COLUMBA Study Investigating a Subcutaneous Formulation of DARZALEX® (daratumumab) Showed Non-Inferiority to Intravenous Administration in Patients with Relapsed/Refractory Multiple Myeloma

New formulation also showed shorter administration time and lower rate of infusion-related reactions

June 2, 2019
·
21 min read
BioCapital

BioMarker Strategies to Present at the BIO 2019 International Convention in Philadelphia

Demonstrations of the SnapPath® Cancer Diagnostics System Will Be Provided During Exhibit Hours

June 2, 2019
·
2 min read
Drug Development

Celgene Presents Data from a Phase 1/2 Clinical Study of Iberdomide in Combination with Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma at ASCO 2019

Investigational treatment demonstrates favorable early safety and efficacy data in patients who had received a median five prior treatments including immunomodulatory agents, proteasome inhibitors and anti-CD38 agents

June 2, 2019
·
7 min read
Drug Development

DARZALEX® (daratumumab) Investigational Study Shows Increased Depth of Response and Longer Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Eligible for a Transplant

The Phase 3 CASSIOPEIA study is one of the largest transplant studies ever conducted in multiple myeloma, and the largest study conducted with DARZALEX

June 2, 2019
·
22 min read
Pharm Country

Children’s Hospital of Philadelphia Celebrates 23ʳᵈ Annual Fetal Surgery Family Reunion

Yearly event gathers patients and families who were treated in the Center for Fetal Diagnosis and Treatment

June 2, 2019
·
3 min read
Deals

Takeda Makes First Private Sector Pledge for Global Fund Replenishment

Takeda Pharmaceutical Company Limited became the first private sector company to announce a financial commitment to the Global Fund’s Sixth Replenishment.

June 2, 2019
·
4 min read
Deals

INSIGHTEC MR-Guided Focused Ultrasound Receives Reimbursement from Japanese Ministry of Health, Labour and Welfare for the Treatment of Essential Tremor

INSIGHTEC® announced that it has received national reimbursement from the Japanese Ministry of Health, Labour and Welfare for treating essential tremor.

June 2, 2019
·
3 min read